Bioavailability of Pancreatic Enzymes in the Human Upper Intestine (Duodenum and Jejunum)
Not Applicable
Terminated
- Conditions
- Exocrine Pancreatic Insufficiency
- Interventions
- Drug: placebo
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Digestive Care, Inc.
- Target Recruit Count
- 11
- Registration Number
- NCT00749099
Intraduodenal Aspiration Study to Assess the Bioavailability of Oral Pancrecarb® Compared to Placebo Control
Phase 4
Terminated
- Conditions
- Exocrine Pancreatic InsufficiencyChronic PancreatitisCystic Fibrosis
- Interventions
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2013-02-22
- Lead Sponsor
- Digestive Care, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT00744250
- Locations
- 🇺🇸
UNC Healthcare, Chapel Hill, North Carolina, United States
Open Label Safety Study of DCI-1020 in Pediatric Cystic Fibrosis (CF) Patients
Not Applicable
Withdrawn
- Conditions
- Digestive System DiseasesPancreatic DiseaseCystic FibrosisExocrine Pancreatic Insufficiency
- Interventions
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2010-05-13
- Lead Sponsor
- Digestive Care, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00663975
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis
Phase 3
Completed
- Conditions
- Cystic FibrosisPancreatic Insufficiency
- Interventions
- Drug: PANCRECARB® (pancrelipase)Drug: Placebo
- First Posted Date
- 2007-02-08
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Digestive Care, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT00432861
- Locations
- 🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath